Why the study?
Subcutaneous protein C concentrate infusions had been described in infants after severe postnatal thrombosis, but not in newborns or premature infants without thromboembolism.
Does continuous postnatal intravenous and consecutive subcutaneous therapy with protein C concentrate followed by apixaban prevent thromboembolic complications in a preterm infant with compound heterozygous protein C deficiency?
Does continuous postnatal intravenous and consecutive subcutaneous therapy with protein C concentrate followed by apixaban prevent thromboembolic complications in a preterm infant with compound heterozygous protein C deficiency?
Early switch to subcutaneous protein C concentrate infusions and later transition to DOACs provided safe and effective long-term management without thromboembolic complications in a preterm infant with severe protein C deficiency.
No takes yet. Share an insight, caveat, or question.
May support individualized long-term management in severe neonatal protein C deficiency; leaves open generalizability pending prospective data.
Pöschl et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: